Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Positioning of proteasome inhibitors in therapy of solid malignancies
Margot S. F. Roeten, Jacqueline Cloos, Gerrit Jansen
Cancer Chemotherapy and Pharmacology (2017) Vol. 81, Iss. 2, pp. 227-243
Open Access | Times Cited: 128

Showing 26-50 of 128 citing articles:

Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na+/K+-ATPase α1 subunit
Yu‐Long Lan, Xun Wang, Jiacheng Lou, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 103, pp. 204-215
Closed Access | Times Cited: 36
The Ubiquitin‐proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing
Rosa Molfetta, Nadia Domenica Milito, Béatrice Zitti, et al.
European Journal of Immunology (2019) Vol. 49, Iss. 6, pp. 873-883
Open Access | Times Cited: 32
Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress
Cheng-Jung Ho, Ru‐Wei Lin, Weihua Zhu, et al.
Cell Death Discovery (2019) Vol. 5, Iss. 1
Open Access | Times Cited: 31
Functional redundancy of HSPA1, HSPA2 and other HSPA proteins in non-small cell lung carcinoma (NSCLC); an implication for NSCLC treatment
Damian Robert Sojka, Agnieszka Gogler‐Pigłowska, Natalia Vydra, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 30
Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Nicolás A. Fraunhoffer, Analía Meilerman Abuelafia, Martin Bigonnet, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 20, pp. 5506-5519
Open Access | Times Cited: 28
Advances in Proteasome Enhancement by Small Molecules
Dare E. George, Jetze J. Tepe
Biomolecules (2021) Vol. 11, Iss. 12, pp. 1789-1789
Open Access | Times Cited: 27
P53: Stability from the Ubiquitin–Proteasome System and Specific 26S Proteasome Inhibitors
Andressa Barban do Patrocínio, Vanderlei Rodrigues, Lizandra Guidi Magalhães
ACS Omega (2022) Vol. 7, Iss. 5, pp. 3836-3843
Open Access | Times Cited: 18
The Sec61 translocon is a therapeutic vulnerability in multiple myeloma
Antoine Domenger, Caroline Choisy, Ludivine Baron, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 3
Open Access | Times Cited: 17
Proteasome Inhibition Reprograms Chromatin Landscape in Breast Cancer
H. Karimi Kinyamu, Brian D. Bennett, James M. Ward, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 4, pp. 1082-1099
Open Access | Times Cited: 3
Exploring the therapeutic potential of Aloin: unraveling neuroprotective and anticancer mechanisms, and strategies for enhanced stability and delivery
Stefania Zimbone, Valeria Romanucci, Armando Zarrelli, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer
Sally E. Claridge, Shalini Nath, Andrew Baum, et al.
Clinical and Translational Medicine (2025) Vol. 15, Iss. 2
Open Access
Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death
In Young Kim, Min June Shim, Dong Min Lee, et al.
Biochemical Pharmacology (2018) Vol. 162, pp. 41-54
Closed Access | Times Cited: 29
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
Monica Benvenuto, Sara Ciuffa, Chiara Focaccetti, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 22
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
Tina Paradžik, Cecilia Bandini, Elisabetta Mereu, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1235-1235
Open Access | Times Cited: 21
Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs
Valeria Sanabria Guillen, Yvonne Ziegler, Chirag Gopinath, et al.
Breast Cancer Research and Treatment (2023) Vol. 198, Iss. 3, pp. 607-621
Closed Access | Times Cited: 8
A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases
Maoyuan Tian, Taoling Zeng, Mingdong Liu, et al.
Journal of Biological Chemistry (2018) Vol. 294, Iss. 8, pp. 2880-5770
Open Access | Times Cited: 27
BET Inhibitors Synergize with Carfilzomib to Induce Cell Death in Cancer Cells via Impairing Nrf1 Transcriptional Activity and Exacerbating the Unfolded Protein Response
Janakiram R. Vangala, Ajay Potluri, Senthil K. Radhakrishnan
Biomolecules (2020) Vol. 10, Iss. 4, pp. 501-501
Open Access | Times Cited: 22
Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7–APEH–Proteasome Axis in High-grade Serous Ovarian Carcinoma
Apoorva Tangri, Kinzie Lighty, Jagadish Loganathan, et al.
Molecular Cancer Research (2021) Vol. 19, Iss. 7, pp. 1168-1181
Open Access | Times Cited: 20
LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression
Mohamad Moustafa Ali, Mirco Di Marco, Sagar Mahale, et al.
Oncogene (2021) Vol. 40, Iss. 13, pp. 2463-2478
Closed Access | Times Cited: 19
Long-term treatment with chloroquine increases lifespan in middle-aged male mice possibly via autophagy modulation, proteasome inhibition and glycogen metabolism
Thorsten R. Doeppner, Cristin Coman, Daiana Burdusel, et al.
Aging (2022) Vol. 14, Iss. 10, pp. 4195-4210
Open Access | Times Cited: 14
Graphene Oxide Nanoscale Platform Enhances the Anti‐Cancer Properties of Bortezomib in Glioblastoma Models
Paul Sharp, Maria Stylianou, Luis M. Arellano, et al.
Advanced Healthcare Materials (2022) Vol. 12, Iss. 3
Open Access | Times Cited: 14
Proteasome inhibitors as anticancer agents
Giorgia Gazzaroli, Andrea Angeli, Arianna Giacomini, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 11, pp. 775-796
Closed Access | Times Cited: 7
Nrf1-mediated transcriptional regulation of the proteasome requires a functional TIP60 complex
Janakiram R. Vangala, Senthil K. Radhakrishnan
Journal of Biological Chemistry (2018) Vol. 294, Iss. 6, pp. 2036-2045
Open Access | Times Cited: 22
Synthetic lethality: a step forward for personalized medicine in cancer
Heena Jariyal, Frank Weinberg, Abhinav Achreja, et al.
Drug Discovery Today (2019) Vol. 25, Iss. 2, pp. 305-320
Closed Access | Times Cited: 22
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload
A Reum Lee, Min Ji Seo, Jin Kim, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 24, pp. 6112-6112
Open Access | Times Cited: 20

Scroll to top